12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VRC DNA/rAd5 HIV vaccine regimen: Phase IIb discontinued

NIH's National Institute of Allergy and Infectious Diseases (NIAID) discontinued the double-blind, placebo-controlled, U.S. Phase IIb HVTN 505 trial after an interim analysis by an independent DSMB showed that the VRC DNA/rAd5 HIV vaccine regimen did not prevent HIV infection nor reduce viral load in vaccine recipients who became infected with HIV. Specifically, in subjects who were in the trial for a minimum of 28 weeks, there were 27 cases of HIV infection in...

Read the full 346 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >